BioSpace News Archive

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and a network of high-complexity labs to deliver saliva-based COVID-19 testing.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 72 new employees with a grant date of November 15, 2020 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stoc

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company’s recent developments during an investor webinar on Thursday, November 19, 2020 at 4:15 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation. To participate in the webinar, please register at: https://www.redchip.com/cor

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications

Interactive MoneyShow Virtual Expo features access to companies at the forefront of technological innovation that have served as driving factors in the robust market we have witnessed over at least the last decade.

Chiesi USA, a specialty pharmaceutical company based in Cary, N.C., is proud to once again support March of Dimes in its mission to improve the health and lives of moms and babies during November’s Prematurity Awareness Month observance.

Sysmex America, Inc., a leading diagnostic company offering hematology, urinalysis, informatics systems and flow cytometry testing solutions for optimal clinical laboratory performance, today announced it will add the CellaVision® DC-1 to its portfolio of CellaVision products for low-volume hematology lab

Micro-Tech Endoscopy USA continues its streak of new product launches with the introduction of four new GI accessory kits.

- Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 - - Trial In Progress Poster of Phase 2 TENACITY Study of AL101 Monotherapy in Patients w ith Notch-activated Triple-Negative Breast Cance r Accepted for Presentation at San Antonio Breast Cancer Virtual Symposium -

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that data from RHAPSODY, the pivotal Phase 3 trial of rilonacept in recurrent pericarditis, were published in The New England Journal of Medicine . Additionally, the RHAPSODY data were presented at the late-breaking science session dur